Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 16 Issue 4, December 2022

In this issue...

• Biopharma deals of 2022

• Exploring the cell and gene landscape

• Uncovering a new generation of microbial-based therapeutics

• Dealmaking for immuno-inflammatory diseases

3D illustration of microorganisms under a microscope such as intestinal bacteria. Siarhei Yurchanka / Alamy Stock Photo.

Industry shows trust in cell and gene therapy platform technologies

Top of page ⤴

Seeking therapeutic opportunities amid the complexity of the microbiome

Top of page ⤴

Innovative approaches to treat immuno-inflammatory diseases

  • Feature

  • Profiles

    • CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.

      • CalciMedica Inc.
      Advertisement Feature
    • Enterome is using its unique Mimicry approach coupled with the power of partnering to harness the potential of the gut’s natural tolerance pathway to address allergies and autoimmune diseases.

      • Enterome
      Advertisement Feature
Top of page ⤴

Top ten deals of 2022

  • Feature

    • Dealmaking is returning to pre-pandemic levels with numerous billion-dollar deals being signed, many focusing on immuno-oncology and inflammation.

      • Biopharma Dealmakers
      • DealForma, LLC
      News Feature
  • Profiles

    • First Republic Bank’s relationships in the sector help it meet the unique needs of both startups and seasoned life science companies.

      • First Republic Bank
      Advertisement Feature
    • As a government funder, the Korea Drug Development Fund (KDDF) invests in promising selected compounds by taking them through assessment and translating them into cutting-edge science for patient benefits and market opportunities.

      • Korea Drug Development Fund
      Advertisement Feature
    • The city of Phoenix hosts a thriving life-sciences ecosystem that fosters collaboration among industry, education, research and community partners to transform discoveries into health.

      • City of Phoenix Community and Economic Development Department
      Advertisement Feature
    • Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.

      • Glyscend, Inc.
      Advertisement Feature
    • Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.

      • MetasTx
      Advertisement Feature
Top of page ⤴

Search

Quick links